Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial
…, DF Merlo, S Cavuto, L Savoldi, P Bruzzi… - JAMA internal …, 2021 - jamanetwork.com
Importance The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of
people worldwide. Tocilizumab has shown promising results in retrospective studies in …
people worldwide. Tocilizumab has shown promising results in retrospective studies in …
[HTML][HTML] Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy
…, KM Harris, P Bernabň, P Bruzzi… - … England Journal of …, 2000 - Mass Medical Soc
Background Sudden death is a possible consequence of hypertrophic cardiomyopathy.
Quantification of the risk of sudden death, however, remains imprecise for most patients with this …
Quantification of the risk of sudden death, however, remains imprecise for most patients with this …
Estimating the population attributable risk for multiple risk factors using case-control data
P Bruzzi, SB Green, DP Byar, LA Brinton… - American journal of …, 1985 - academic.oup.com
A straightforward and unified approach is presented for the calculation of the population
attributable risk per cent (etiologic fraction) in the general muftivariate setting, with emphasis on …
attributable risk per cent (etiologic fraction) in the general muftivariate setting, with emphasis on …
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy
…, F Arribas, MV Sherrid, G Buja, C Semsarian, P Bruzzi - Jama, 2007 - jamanetwork.com
ContextRecently, the implantable cardioverter-defibrillator (ICD) has been promoted for
prevention of sudden death in hypertrophic cardiomyopathy (HCM). However, the effectiveness …
prevention of sudden death in hypertrophic cardiomyopathy (HCM). However, the effectiveness …
Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo …
A Bacigalupo, T Lamparelli, P Bruzzi… - Blood, The Journal …, 2001 - ashpublications.org
One hundred nine patients with hematologic malignancies, undergoing bone marrow transplants
(BMT) from unrelated donors, were randomized in 2 consecutive trials to receive or not …
(BMT) from unrelated donors, were randomized in 2 consecutive trials to receive or not …
[HTML][HTML] Adjuvant mitotane treatment for adrenocortical carcinoma
…, P Loli, G Lombardi, M Mannelli, P Bruzzi… - … England Journal of …, 2007 - Mass Medical Soc
Background Adrenocortical carcinoma is a rare neoplasm characterized by a high risk of
recurrence after radical resection. Whether the use of mitotane is beneficial as an adjuvant …
recurrence after radical resection. Whether the use of mitotane is beneficial as an adjuvant …
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non …
…, M Bregni, CG Stampino, P Bruzzi… - The lancet …, 2009 - thelancet.com
Background Procedures to prevent severe graft-versus-host disease (GVHD) delay immune
reconstitution secondary to transplants of haploidentical haemopoietic stem cells for the …
reconstitution secondary to transplants of haploidentical haemopoietic stem cells for the …
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open …
…, JM Coindre, AP Dei Tos, P Picci, P Bruzzi… - The Lancet …, 2017 - thelancet.com
Background Previous trials from our group suggested an overall survival benefit with five
cycles of adjuvant full-dose epirubicin plus ifosfamide in localised high-risk soft-tissue sarcoma …
cycles of adjuvant full-dose epirubicin plus ifosfamide in localised high-risk soft-tissue sarcoma …
HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials
…, M Colozza, U Pfeffer, P Bruzzi - JNCI: Journal of the …, 2008 - academic.oup.com
Background Adjuvant chemotherapy with anthracyclines improves disease-free and overall
survival compared with non–anthracycline-based adjuvant chemotherapy regimens in the …
survival compared with non–anthracycline-based adjuvant chemotherapy regimens in the …
[HTML][HTML] Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized …
…, T Lamparelli, G Barisione, P Bruzzi… - Biology of Blood and …, 2006 - Elsevier
This is an update of a randomized study on antithymocyte globulin (ATG; Thymoglobulin)
before transplantation in patients undergoing unmanipulated marrow transplantation from …
before transplantation in patients undergoing unmanipulated marrow transplantation from …